These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 25921217)
1. Exploring the molecular basis of action of ring D aromatic steroidal antiestrogens. Alvarez LD; Veleiro AS; Burton G Proteins; 2015 Jul; 83(7):1297-306. PubMed ID: 25921217 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of salpichrolide analogs as antiestrogenic agents. Sonego JM; Rivero EM; Gargiulo L; Lüthy I; Alvarez LD; Veleiro AS; Burton G Eur J Med Chem; 2014 Jul; 82():233-41. PubMed ID: 24908652 [TBL] [Abstract][Full Text] [Related]
3. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics. Celik L; Lund JD; Schiøtt B Biochemistry; 2007 Feb; 46(7):1743-58. PubMed ID: 17249692 [TBL] [Abstract][Full Text] [Related]
4. Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis. Moldogazieva NT; Ostroverkhova DS; Kuzmich NN; Kadochnikov VV; Terentiev AA; Porozov YB Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019136 [TBL] [Abstract][Full Text] [Related]
5. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. Sharma A; Toy W; Guillen VS; Sharma N; Min J; Carlson KE; Mayne CG; Lin S; Sabio M; Greene G; Katzenellenbogen BS; Chandarlapaty S; Katzenellenbogen JA ACS Chem Biol; 2018 Dec; 13(12):3374-3384. PubMed ID: 30404440 [TBL] [Abstract][Full Text] [Related]
6. Ligand unbinding from the estrogen receptor: a computational study of pathways and ligand specificity. Burendahl S; Danciulescu C; Nilsson L Proteins; 2009 Dec; 77(4):842-56. PubMed ID: 19626711 [TBL] [Abstract][Full Text] [Related]
7. Estrogenic activity of bis(4-hydroxyphenyl)methanes with cyclic hydrophobic structure. Kojima T; Ogawa T; Kitao S; Sato M; Oda A; Ohta K; Endo Y Bioorg Med Chem; 2015 Nov; 23(21):6900-11. PubMed ID: 26462053 [TBL] [Abstract][Full Text] [Related]
8. Three- and four-body corrected fragment molecular orbital calculations with a novel subdividing fragmentation method applicable to structure-based drug design. Watanabe C; Fukuzawa K; Okiyama Y; Tsukamoto T; Kato A; Tanaka S; Mochizuki Y; Nakano T J Mol Graph Model; 2013 Apr; 41():31-42. PubMed ID: 23467020 [TBL] [Abstract][Full Text] [Related]
9. From ligand structure to biological activity: modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells. Brooks SC; Skafar DF Steroids; 2004 Jun; 69(6):401-18. PubMed ID: 15219790 [TBL] [Abstract][Full Text] [Related]
10. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha. Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373 [TBL] [Abstract][Full Text] [Related]
11. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α. Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700 [TBL] [Abstract][Full Text] [Related]
12. Computational insights into the mechanism of ligand unbinding and selectivity of estrogen receptors. Shen J; Li W; Liu G; Tang Y; Jiang H J Phys Chem B; 2009 Jul; 113(30):10436-44. PubMed ID: 19583238 [TBL] [Abstract][Full Text] [Related]
13. Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha. Geetha Rani Y; Lakshmi BS J Biomol Struct Dyn; 2019 Mar; 37(5):1189-1203. PubMed ID: 29557271 [TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands. Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935 [TBL] [Abstract][Full Text] [Related]
15. Deciphering the GPER/GPR30-agonist and antagonists interactions using molecular modeling studies, molecular dynamics, and docking simulations. Méndez-Luna D; Martínez-Archundia M; Maroun RC; Ceballos-Reyes G; Fragoso-Vázquez MJ; González-Juárez DE; Correa-Basurto J J Biomol Struct Dyn; 2015; 33(10):2161-72. PubMed ID: 25587872 [TBL] [Abstract][Full Text] [Related]
16. Activation helix orientation of the estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations. Fratev F Phys Chem Chem Phys; 2015 May; 17(20):13403-20. PubMed ID: 25927714 [TBL] [Abstract][Full Text] [Related]
17. Insights into ligand selectivity in estrogen receptor isoforms: molecular dynamics simulations and binding free energy calculations. Zeng J; Li W; Zhao Y; Liu G; Tang Y; Jiang H J Phys Chem B; 2008 Mar; 112(9):2719-26. PubMed ID: 18266357 [TBL] [Abstract][Full Text] [Related]
18. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Anstead GM; Carlson KE; Katzenellenbogen JA Steroids; 1997 Mar; 62(3):268-303. PubMed ID: 9071738 [TBL] [Abstract][Full Text] [Related]
19. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635 [TBL] [Abstract][Full Text] [Related]
20. Constructing an atomic-resolution model of human P2X7 receptor followed by pharmacophore modeling to identify potential inhibitors. Ahmadi M; Nowroozi A; Shahlaei M J Mol Graph Model; 2015 Sep; 61():243-61. PubMed ID: 26298810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]